ライフサイエンスコーパス: angiogenic factor

1 ysteine-rich, angiogenic inducer 61 (a known angiogenic factor).

2 porting Netrin-4 as either a pro- or an anti-angiogenic factor.

3 ional vessel development, acting as a potent angiogenic factor.

4 pel-Trenaunay syndrome (KTS), and encodes an angiogenic factor.

5 ion, uptake, and decay of tumor-secreted pro-angiogenic factor.

6 c acid decreases expression of this critical angiogenic factor.

7 ain 7 (EGFL7), an extracellular matrix-bound angiogenic factor.

8 l growth factor (VEGF) is the most important angiogenic factor.

9 n (FMOD), which we determined to be a potent angiogenic factor.

10 ted with downregulation of several important angiogenic factors.

11 nherently express and secrete high levels of angiogenic factors.

12 , metastases, secretion of cytokines and pro-angiogenic factors.

13 iated accumulation of HIF-1alpha and related angiogenic factors.

14 pondin-1 (TSP-1) and its receptor CD36, anti-angiogenic factors.

15 developing vessel networks exposed to excess angiogenic factors.

16 as chaperones, hormone transporters, or anti-angiogenic factors.

17 al protein synthesis, and down-regulation of angiogenic factors.

18 d to upregulation of NF-kappaB-derived tumor angiogenic factors.

19 matory cells, cytokines, growth factors, and angiogenic factors.

20 ioscaffolds or bioscaffolds not treated with angiogenic factors.

21 g and is mediated by a plethora of potential angiogenic factors.

22 p-regulating production of Th2 cytokines and angiogenic factors.

23 e biological processes that are regulated by angiogenic factors.

24 on of several cytokines, growth factors, and angiogenic factors.

25 kappaB and several cytokines, and growth and angiogenic factors.

26 real-time PCR, and Western blot analysis of angiogenic factors.

27 Rs on inflammatory cells modulate release of angiogenic factors.

28 n neoplastic processes because of release of angiogenic factors.

29 r endothelial growth factor (VEGF) family of angiogenic factors.

30 by the relative concentrations of these key angiogenic factors.

31 tion has been observed after the delivery of angiogenic factors.

32 oliferation and the production of growth and angiogenic factors.

33 ing hypoxia-inducible factor levels on other angiogenic factors.

34 ascular repair by paracrine secretion of pro-angiogenic factors.

35 promoting the highest increases in EPCs and angiogenic factors.

36 nes, as well as genes encoding receptors for angiogenic factors.

37 proteins, granulation tissue components, and angiogenic factors.

38 ealed that IL1R2 activates the expression of angiogenic factors.

39 rowth and metastasis and is dependent on key angiogenic factors.

40 gulated by the balance between pro- and anti-angiogenic factors.

41 erular endotheliosis, and production of anti-angiogenic factors.

42 Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated plac

43 tokine IL-8 and increased levels of the anti-angiogenic factors activin-A and pigment epithelium-deri

44 proliferation, migration, and expression of angiogenic factors, additional factors and environmental

45 e fibroblast growth factor (FGF) is a potent angiogenic factor and aberrant FGF signaling is a common

46 uidance molecule Slit3 is a novel and potent angiogenic factor and functions to promote angiogenesis

47 growth factor (VEGF) is the most potent pro-angiogenic factor and is regulated by pathways related t

48 helial growth factor (VEGF) is a predominant angiogenic factor and its dosage is precisely regulated

49 results demonstrate that NPNT is a paracrine angiogenic factor and may play a role in pathological os

50 val and transformation, IL-8 functions as an angiogenic factor and pro-survival signal, and ICAM-1 ha

51 in glucose transporters, glycolytic enzymes, angiogenic factors and cardiac morphology were examined

52 adhesion, and the autocrine release of some angiogenic factors and extracellular matrix components.

53 investigated the expression and secretion of angiogenic factors and found reduced mRNA, protein, and

54 Using this model, we screened the effects of angiogenic factors and identified two distinct cocktails

55 by simultaneously down-regulating potent pro-angiogenic factors and inducing endogenous anti-angiogen

56 si's sarcoma lesion expresses high levels of angiogenic factors and is comprised of a mixed cell popu

57 imited because of insufficient expression of angiogenic factors and low cell viability after transpla

58 eatment, and then, we assessed expression of angiogenic factors and mechanotransducers (focal adhesio

59 associated with elevated renal expression of angiogenic factors and mechanotransducers, particularly

60 ssion of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular end

61 expression results in reduced expression of angiogenic factors and regression of the lesions.

62 diators of vascular response, including both angiogenic factors and small molecules such as nitric ox

63 d pancreatic expression of three families of angiogenic factors and their receptors in differentiatin

64 for antitumor therapies, and identifying new angiogenic factors and their specific inhibitors may pro

65 Plasma angiogenic factors and VEGFR2 phosphorylation in mononuc

66 etion of multiple cytokines, chemokines, and angiogenic factors and, in particular, with the inductio

67 m is to act as a "survival," rather than an "angiogenic" factor and that VEGF-B inhibition may offer

68 AGGF1 is an angiogenic factor, and its deregulation is associated wi

69 s, inflammatory cells, cytokines, growth and angiogenic factors, and angiogenesis.

70 s a constitutive network of other cytokines, angiogenic factors, and chemokines that may act in an au

71 ells, vascular endothelial cells, diffusible angiogenic factors, and necrosis formation into a first-

72 terplay among hypoxic Muller cells, secreted angiogenic factors, and neighboring ECs in the regulatio

73 ic of endothelial progenitor cells, produced angiogenic factors, and proliferated in vitro.

74 te accumulation, downregulation of pulmonary angiogenic factors, and reduced symptoms of HPS.

75 l growth factors, cytokines, chemokines, and angiogenic factors, and the multifunctional angiogenic p

76 ction of miR-221 and subsequent induction of angiogenic factors Angiogenin and CXCL16.

77 tly target and repress the mRNA encoding the angiogenic factor angiopoietin 1 (ANGPT1), leading to de

78 We hypothesized that deregulation of an angiogenic factor, angiopoietin-2 (Ang-2), in patients w

79 etinas identified an increase in the key pro-angiogenic factor, angiopoietin-2, as the most significa

80 ncluding a reset profile of pro- versus anti-angiogenic factors, apparently distinct for physiologica

81 howed that vascularization and expression of angiogenic factors are evident in the colonic mucosa of

82 Complementary angiogenic factors are therefore regulated by the subcel

83 pression of transcripts for neurotrophic and angiogenic factors, as well as JUN, all of which are ess

84 ocked the overexpression of the inflammatory/angiogenic factors, attenuated leukostasis, and reduced

85 tant regulator of the expression of multiple angiogenic factors, bevacizumab-initiated up-regulation

86 Signaling pathways engaged by angiogenic factors bFGF and VEGF in tumor angiogenesis a

87 3D cultures in expression of most canonical angiogenic factors but suggested changes in several path

88 d by a balance between positive and negative angiogenic factors, but temporal protein expression of m

89 lue light filtering affects the secretion of angiogenic factors by retinal pigmented epithelial cells

90 conducted a broad profiling of cytokine and angiogenic factors (CAF) to investigate the relationship

91 duce changes in these or other cytokines and angiogenic factors (CAFs) and whether such changes could

92 ges during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatm

93 atment plasma concentrations of cytokine and angiogenic factors (CAFs) with data from a phase 2 and a

94 We found that expression of the angiogenic factor CCN1 was increased in the colons of pa

95 In addition, HIMF-induced production of angiogenic factors/chemokines, such as vascular endothel

96 herefore, we hypothesized that a circulating angiogenic factor could predict disease severity and sur

97 tor (Y2R), is an autocrine proliferative and angiogenic factor crucial for maintaining NB tumor growt

98 tion resulted in decreased production of pro-angiogenic factors, CXCL1 and vascular endothelial growt

99 ic PAR1 expression induces expression of the angiogenic factor Cyr61(CCN1) in breast cancer cells.

100 , VEGF-independent, clinically relevant, pro-angiogenic factor, CYR61, that is a transcriptional targ

101 , regulatory T-cell numbers, and circulating angiogenic factors did not predict outcome.

102 ession of anti-apoptotic, pro-oncogenic, and angiogenic factors during tumor progression.

103 vascular endothelial growth factor and other angiogenic factors (eg, ANG [angiogenin], TIMP1/2 [tissu

104 The angiogenic factor Egfl6 was expressed by the K15- bulge

105 Both angiogenic factors enhanced pulp microvessel density com

106 VEGF-A, a potent vascular permeabilizing and angiogenic factor, exerts much of its angiogenic activit

107 ar endothelial growth factor (VEGF) is a key angiogenic factor expressed under restricted nutrient an

108 sue vascularity, possibly reflecting altered angiogenic factor expression in infected cells.

109 ween maternal periodontal disease and plasma angiogenic factor expression of soluble fms-like tyrosin

110 Angiogenesis and angiogenic factor expression were measured by immunohist

111 ern blot of infected cultured cells measured angiogenic factor expression.

112 ollateral vessel formation and inhibition of angiogenic factors expression and actions.

113 , we show that, similar to a number of other angiogenic factors, expression of the apelin gene is inc

114 aranase activity releases growth factors and angiogenic factors from heparan sulfate (HS) storage sit

115 ogenesis; they also stimulated production of angiogenic factors from HIMEC and HIF, and HIF-derived a

116 activation induces the secretion of several angiogenic factors from ovarian carcinoma cells, most pr

117 lation of differentially mediated release of angiogenic factors from platelets may provide a new moda

118 RBPJ controls angiogenic factor gene expression independently of Notch

119 tions show: 1), different tumor-secreted pro-angiogenic factor gradient profiles dramatically affect

120 The overexpression of the angiogenic factors has been demonstrated in HCC.

121 of angiogenesis in various diseases and many angiogenic factors have been discovered as therapeutic t

122 PlGF emerged as the most efficient and safe angiogenic factor, hence making it a candidate for thera

123 st evidence linking the complement system to angiogenic factor imbalance associated with placental dy

124 of stem cell factor (SCF), an important pro-angiogenic factor in GBM.

125 IL-32 could function as an inflammatory and angiogenic factor in human obesity and obesity-associate

126 r endothelial growth factor-A mRNA, a potent angiogenic factor in the settings of tumor development a

127 ar endothelial growth factor (VEGF) is a key angiogenic factor in tumors, but less is known about wha

128 however, by the current inability to deliver angiogenic factors in a sustained manner at the site of

129 The prognostic significance of angiogenic factors in adult acute lymphoblastic leukemia

130 In the absence of prematurity, UPI increased angiogenic factors in association with reduced OIR sever

131 L2 was found to induce expression of several angiogenic factors in brain endothelial cells.

132 tor signaling linked to up-regulation of pro-angiogenic factors in cardiac Sca-1(+)CD31(-) stromal ce

133 ct the biological activity driven by the two angiogenic factors in endothelial cells, as evidenced by

134 We aimed to evaluate the expression of angiogenic factors in hepatitis C virus (HCV)-HCC tissue

135 nge of chemokines, cytokines, and growth and angiogenic factors in MAPK inhibitor-treated metastatic

136 y mechanotransduction-mediated expression of angiogenic factors in proximal tubular cells, and it may

137 or the HDM2 oncoprotein in the regulation of angiogenic factors in renal cell carcinoma.

138 xpression of several pro-angiogenic and anti-angiogenic factors in response to (1) a single acute bou

139 Temporal expression of positive and negative angiogenic factors in response to detraining is poorly u

140 To examine the role of angiogenic factors in the coordinated development of isl

141 ate that there is an increased expression of angiogenic factors in the liver in different mouse model

142 sm that induces the expression of growth and angiogenic factors in tumors, leading to their local inc

143 a opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors.

144 n block the autocrine and paracrine loops of angiogenic factors in vascular endothelial and cancer ce

145 e progenitors proliferate in response to pro-angiogenic factors, in association with expanding capill

146 Angiogenic factors including phospho-Akt, phospho-eNOS,

147 nt also did not change retinal expression of angiogenic factors including vascular endothelial growth

148 ctors, such as endostatin, and decreased pro-angiogenic factors, including CXC motif ligand 1 (CXCL1)

149 HIF-2alpha-dependent expression of specific angiogenic factors, including delta-like ligand 4 (Dll4)

150 cells and impaired production of several key angiogenic factors, including the vascular endothelial g

151 on of angiogenesis and upregulation of other angiogenic factors, including vascular endothelial growt

152 stimulation also induced a broad program of angiogenic factors, including vascular endothelial growt

153 Further, the production of angiogenic factors, including vascular endothelial growt

154 progression, and they involve the release of angiogenic factors, including vascular endothelial growt

155 tube formation assay via Stat3 induction of angiogenic factors, including VEGF and bFGF.

156 Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine

157 duction, microRNA-210 can upregulate several angiogenic factors, inhibit caspase activity, and preven

158 ficantly higher expression levels of the pro-angiogenic factor interleukin (IL)-8 in human glioma spe

159 elease of proinflammatory cytokines and anti-angiogenic factors into the maternal circulation.

160 closely associated with liver fibrosis, the angiogenic factors involved in liver fibrosis are not we

161 We show that regulation of these angiogenic factors is dependent on ERK1/2 phosphorylatio

162 endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in self-renewal in

163 VEGF-A, an angiogenic factor, is increased in the peritoneal fluid

164 monstrate that empowerment of uNK cells with angiogenic factors keeps them noncytotoxic.

165 r endothelial growth factor (VEGF) and other angiogenic factors, leading to neovascularization and pr

166 Transient increases in angiogenic factor levels and prolonged hyperemia charact

167 ways involving hypoxia-inducible factors and angiogenic factors like VEGF, oxidative species, and neu

168 ated with beta-LGND2 had lower levels of pro-angiogenic factors, like VEGF and HIF1alpha.

169 ong with induction of other invasiveness and angiogenic factors may combine to act in a complex seque

170 However, other angiogenic factors may contribute to the overall angioge

171 wth factor-like growth factor (HB-EGF) is an angiogenic factor mediating radial migration of the deve

172 Soluble angiogenic factors might be useful for monitoring high-r

173 ially in response to the combined effects of angiogenic factors, migratory cues via the extracellular

174 pressed Akr1b7, and maturing cells expressed angiogenic factors necessary for the development of the

175 Although both NotchICD groups expressed angiogenic factors, Notch4ICD had selective vascular end

176 To examine the effect of angiogenic factors on the disease progression of NASH, a

177 ted the effect of miR200-b, a potential anti-angiogenic factor, on VEGF receptor 2 (VEGFR-2) expressi

178 sia (PE) are primarily driven by excess anti-angiogenic factors originating from the placenta.

179 n endothelial function and the regulation of angiogenic factor pathways important for vascular homeos

180 ting, thereby confirming the hypothesis that angiogenic factors play an early role in the disease pro

181 An imbalance in circulating angiogenic factors plays a central role in the pathogene

182 ether matrix metalloproteinase-9 (MMP-9), an angiogenic factor predominantly produced by osteoclasts

183 s and suggest that topical application of an angiogenic factor prior to replantation might be benefic

184 EGFL7 is a secreted angiogenic factor produced by embryonic endothelial cell

185 rated that placenta growth factor (PlGF), an angiogenic factor produced by erythroid cells, induces h

186 angiogenic vessels, apparently stimulated by angiogenic factors produced by mesothelial cells.

187 kinetics, and proliferative responses toward angiogenic factors progressively resembled those of HDME

188 d islet development while islet cell-derived angiogenic factors promote EC recruitment and extensive

189 Angiogenic factors promote mobilization of vascular endo

190 factors from HIMEC and HIF, and HIF-derived angiogenic factors promoted HIMEC proliferation.

191 cell fenestration, proliferation, and islet angiogenic factor/receptor expression were unchanged in

192 excess centrosomes, suggesting that multiple angiogenic factors regulate centrosome number.

193 we show that inflammatory cytokines, but not angiogenic factors, regulate delta-catenin expression, a

194 A stimulated AEC proliferation and regulated angiogenic factor release.

195 ate gradients of biochemical signals such as angiogenic factors released by tumors into the surroundi

196 ased significantly after PPVL, whereas other angiogenic factors remained unchanged.

197 ement activation causes dysregulation of the angiogenic factors required for normal placental develop

198 as are classic examples of angiogenesis, the angiogenic factors responsible for hemangiomas are not f

199 n, specifically by investigating the role of angiogenic factors secreted by prostate cancer cells whi

200 tation under cyclic stretching, supported by angiogenic factors secreted in response to each stretch

201 One important outcome is that by reducing angiogenic factor secretion by cancer cells, aspirin als

202 The angiogenic factors soluble fms-like tyrosine kinase 1 an

203 EPCs increased renal expression of angiogenic factors, stimulated proliferation and maturat

204 In addition, the angiogenic factors stromal cell-derived factor 1 (SDF-1a

205 e of IL-18 in up-regulating secretion of the angiogenic factors stromal cell-derived factor 1alpha (S

206 ith mechanical strain-dependent induction of angiogenic factors such as CCN1, an immediate-early gene

207 nt upregulation of key proliferation and pro-angiogenic factors such as Pdgfa, Pdgfb and Vegf.

208 angiogenesis, likely by down-regulating pro-angiogenic factors such as vascular endothelial growth f

209 that angiogenesis and the expression of pro-angiogenic factors such as vascular endothelial growth f

210 apies for tumors that express high levels of angiogenic factors such as VEGF may vary in their effica

211 rmation indicates that the expression of pro-angiogenic factors such as VEGFs and angiogenesis play a

212 enic therapy might implicate alternative pro-angiogenic factors, such as basic fibroblast growth fact

213 hile exhibiting increased expression of anti-angiogenic factors, such as endostatin, and decreased pr

214 1 knockdown downregulated various growth and angiogenic factors, such as HIF1alpha, VEGF and CD31, in

215 However, expression of angiogenic factors, such as vascular endothelial growth

216 trosome number is regulated by signaling via angiogenic factors, such as VEGF.

217 and extracellular matrix as well as soluble angiogenic factors, such as VEGF.

218 n the presence of Vegf and other established angiogenic factors, suggesting either that the levels of

219 induced increased production of most of the angiogenic factors tested (i.e., epidermal growth factor

220 lly, murine endoglin ECD-Fc acted as an anti-angiogenic factor that decreased blood vessel sprouting

221 EGFL7 is a secreted angiogenic factor that is highly conserved in vertebrate

222 Pleiotrophin (PTN) is an angiogenic factor that is produced by many different hum

223 ANG is the only human angiogenic factor that possesses ribonucleolytic activit

224 r results demonstrate that SMOC-2 is a novel angiogenic factor that potentiates angiogenic effects of

225 factor (VEGF) is recognized as an important angiogenic factor that promotes angiogenesis in a series

226 The VEGF-angiopoietin-1 chimera is a potent angiogenic factor that triggers a novel mode of VEGF rec

227 lastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells,

228 However, data regarding specific angiogenic factors that are secreted within the bone mic

229 retina has been postulated to be a source of angiogenic factors that cause aberrant angiogenesis and

230 Therefore, it is important to identify novel angiogenic factors that play essential roles in tumor an

231 d intracellular mechanisms downstream of pro-angiogenic factors that regulate sprout formation and in

232 However, the identity of angiogenic factors that support reconstitution of BM's v

233 arrow microenvironment secrete cytokines and angiogenic factors that support the maintenance and rege

234 report that histamine and serotonin are also angiogenic factors that, at low micromolar concentration

235 xia inducible factor-1alpha, VEGF, and other angiogenic factors, thereby directly supporting prolifer

236 lthough fibroblast growth factors are potent angiogenic factors, they may indirectly control neovascu

237 lls is the repression of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

238 It acts as an angiogenic factor through multiple mechanisms that inclu

239 Tumors secrete pro-angiogenic factors to induce the ingrowth of blood vesse

240 esponse in growth, extracellular matrix, and angiogenic factors to mediate the observed morphological

241 cycline activator transgene and a tet-operon-angiogenic factor transgene) to increase the beta cell p

242 c growth factors but increased expression of angiogenic factors, transitioning to a more neurotoxic a

243 5-N,OS(H) binds a variety of heparin-binding angiogenic factors upregulated in PDR vitreous humor bes

244 resses transcription of the neurotrophic and angiogenic factor vascular endothelial growth factor (VE

245 rrelated with an increased expression of the angiogenic factor vascular endothelial growth factor (VE

246 e migration-inhibitory factor (MIF), and the angiogenic factor vascular endothelial growth factor (VE

247 s pathway regulates production of the potent angiogenic factor vascular endothelial growth factor (VE

248 n of ERK1/2, and decreased expression of the angiogenic factor vascular endothelial growth factor (VE

249 ssential for normal vision, and although the angiogenic factor vascular endothelial growth factor A (

250 The transcript of the angiogenic factor vascular endothelial growth factor A (

251 TNF-alpha levels, reduction of the essential angiogenic factor vascular endothelial growth factor, an

252 ntiates HIF-1-dependent transcription of the angiogenic factor vascular endothelial growth factor-A (

253 L3), Mip-2 (CXCL2), and MCP-1 (CCL2) and the angiogenic factor vascular endothelial growth factor.

254 and up-regulates in vitro expression of the angiogenic factor vascular endothelial growth factor.

255 dothelial area and in mRNA levels of the pro-angiogenic factors vascular endothelial growth factor an

256 ese cells was supported by identification of angiogenic factors (vascular endothelial growth factor,

257 din-1, TSP-1; and endostatin) as well as pro-angiogenic factors (vascular endothelial growth factor,

258 Originally identified as an angiogenic factor, vascular endothelial growth factor (V

259 reased secretion of the HIF-1alpha-regulated angiogenic factor, vascular epidermal growth factor, and

260 in leads to inhibition of COX-2-mediated pro-angiogenic factors, vascular endothelial growth factor,

261 reased levels of membrane attack complex and angiogenic factors-vascular endothelial growth factor an

262 increased concentrations of glucose and the angiogenic factor VEGF as well as higher expression of E

263 cell growth, and decreased the secretion of angiogenic factor VEGF in vitro.

264 au gene upregulate expression of the central angiogenic factor VEGF, which drives abnormal angiogenes

265 The activation of Akt by the potent angiogenic factor VEGF-A does not strongly stabilize mic

266 GATA4 induced the angiogenic factor VEGF-A, directly binding the Vegf-A pr

267 the tumor core and reduced expression of the angiogenic factor VEGF-A.

268 in regulating T cell production of the major angiogenic factor VEGF.

269 corresponding to decreased expression of the angiogenic factor VEGF.

270 PARgamma)-inducible expression of the potent angiogenic factors VEGF-A, apelin, and angiopoietin-like

271 As multiple angiogenic factors (VEGF and basic fibroblast growth fac

272 indirectly by stimulating the production of angiogenic factors (VEGF) by PDL cells.

273 HOXB9 induces the expression of several angiogenic factors (VEGF, bFGF, IL-8, and ANGPTL-2), as

274 treated with growth factors (IGF-1, M-CSF), angiogenic factors (VEGF, IL-8), and matrix proteins fou

275 EPO; (2) diminished expression of the potent angiogenic factor, VEGF; and (3) decreased microvascular

276 against multiple tyrosine kinases, including angiogenic factors VEGFR and PDGFR.

277 within the endocrine pancreas; expression of angiogenic factors was assessed by immunohistochemistry

278 gulating levels of Hif-1alpha, expression of angiogenic factors was decreased in Siah2(-/-) tumors.

279 In all 3 groups a higher expression of the angiogenic factors was encountered in adjacent liver par

280 ormation, gene expression, and production of angiogenic factors was evaluated over time.

281 ial growth factor-A (VEGF-A), the best known angiogenic factor, was originally discovered as a potent

282 By quantifying the levels of host angiogenic factors, we demonstrated that basic fibroblas

283 ficantly up-regulates their secretion of pro-angiogenic factors, we hypothesized that ablation of the

284 Given the role of hypoxia in upregulating angiogenic factors, we hypothesized that the distributio

285 sufficient affinity of the DAF to block both angiogenic factors, we turned to deep mutational scannin

286 Several pazopanib target genes and other angiogenic factors were dysregulated post-treatment.

287 mRNA expression of HIF-1alpha and associated angiogenic factors were evaluated by pimonidazole hydroc

288 Furthermore, 53 angiogenic factors were examined via protein array and c

289 ation, tube formation, and production of pro-angiogenic factors were measured.

290 tion experiments, apelin peptide is a potent angiogenic factor when tested using two in vivo angiogen

291 ents pretreated with bioscaffolds containing angiogenic factors when compared with those who received

292 modulate stromal cells to produce growth and angiogenic factors, which in turn provide the tumor with

293 Acute myeloid leukemia (AML) cells produce angiogenic factors, which likely contribute to this remo

294 R, are required for macrophage production of angiogenic factors, which play critical roles in the neo

295 ll as several cytokines, growth factors, and angiogenic factors, which were significantly affected by

296 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic factors whose synthesis is driven by hypoxia.

297 AGGF1 is an angiogenic factor with therapeutic potential to treat co

298 As a result, we identified Cyr61, an angiogenic factor with unknown neuronal function, as a n

299 rogels to sequester endogenously synthesized angiogenic factors within the matrix.

300 -induced neovascularization and secretion of angiogenic factors within the tumor microenvironment.